New book by Larry Connors Click here Improve your trading - See how
 |
|
Receive Alerts Free For One Week! Short Term PowerRatings Use PowerRatings every day to find the stocks for tomorrow to focus on and the ones to avoid. Sign Up Now >>
Long Term PowerRatings
Gary Kaltbaum Intraday Breaking Setups
Kevin Haggerty's Professional Trading Service
|
A preponderance of medical/drug related companies have earned slots in the top levels of Long Term PowerRatings this week.
Our statistically valid, long term studies have clearly shown that stocks that are awarded a 9 rating have a 79.1% chance of being higher one year later, those with a 10 rating up the ante even further with a 81% chance being higher one year later. These top rated stocks have also proven to be less volatile therefore statistically safer bets for your long term portfolio needs.
On the other end of the spectrum are those stocks that earn a low Long Term PowerRating of 1 or 2. These stocks have proven, over time, to simply be too volatile therefore risky for prudent long term investment. Our testing was done across most market conditions over the last 12 years which validates the ratings as something every investor should look at prior to making any stock investing decision.
Let's take a closer looks at several of the top Power Rated Stocks across the indexes, starting with the DJIA.
Johnson & Johnson (JNJ | Quote | Chart | News | PowerRating) - This drug giant is the number one rated stock in the DJIA with a 6 Long Term PowerRating. They just reported 3rd quarter results with sales up 6.4% and EPS increasing by 10.4% . Technically, a 50 and 200-day simple moving average cross over has just occurred and price has built what looks like a triple bottom at 58 on the chart. However, price is still well below the major simple moving averages.
Kraft Foods (KFT | Quote | Chart | News | PowerRating) - Another 6 rated stock that had a great 3rd quarter. Net Revenues increased 19.4% and diluted EPS more than doubled from last year. They reaffirmed guidance for the rest of the year with positive words about the future. Technically, price has been trading in a rough channel between $26.00 and $30.00/share. Interestingly, the 200-day simple moving average is acting as clear resistance to price at $30.47/share.
The Nasdaq
Cephalon (CEPH | Quote | Chart | News | PowerRating) - This 6 rated drug company remains the number one Long Term PowerRated stock in the Nasdaq index. Their TREANDA drug is thriving and they just reported record sales in the 3rd quarter. Technically, price has just pulled back from a strong uptrend and is sitting directly on the 50-day simple moving average at $72.46/share
Amgen (AMGN | Quote | Chart | News | PowerRating) - The second highest rated stock in the Nasdaq index with a 5 Long Term PowerRating. This biotechnology company has just announced that it has 5 blockbuster drugs in the on the market and 3 more will likely be released over the next several years. Their 3rd quarter EPS increased 14% and technically shares have been uptrending since mid October. Price is currently sitting right on the 50-day simple moving average at $57/52/share
S&P 500
Abbott Labs (ABT | Quote | Chart | News | PowerRating) - The number one ranked stock in the S&P 500 with a 6 Long Term PowerRating. They just reported a 17.6 increase in sales for the 3rd quarter and raised the EPS outlook for 2008. The stock has been very steady over the last several weeks in this extremely volatile environment. Price is above the 200-day simple moving average but below the 50 day. This stock looks like a strong candidate for your watch list.
Baxter International (BAX | Quote | Chart | News | PowerRating) - Another 6 rated stock in the S&P 500. Price has appeared to have found a base at $56/share and they just increased their dividend rate by a whopping 20%. Keep you eye on this medical company!
| Click here to start your free, 7-day trial to our Short Term PowerRatings! |
Learn what you need to know as an active investor looking to invest in companies with a history of financial strength and a track record for growth. Click the link above or call us at 888-484-8220 extension 1 to get your copy of the "5 Secrets to Successful Stock Investing" today!
David Goodboy is Vice President of Marketing for a New York City based multi-strategy fund.
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
